Press Releases

Q1 FY24 Press Release

Q4 FY23 Press Release / News

Q3 FY23 Press Release / News

Press Release in relation to acquisition of ‘Razel’ franchise from Glenmark Pharmaceuticals Limited

Q2 FY23 Press Release / News

Q1 FY23 Press Release

Q4 FY22 Press Release

Q3 FY22 Press Release

Press Release in relation to Acquisition of Brands and Related Assets from Sanzyme Private Limited

Q2 FY22 Earnings Call Transcript

BRIEF-India’s J B Chemicals And Pharmaceuticals Sept-Qtr Consol Net Profit Rises

JB Chemicals & Pharma reports Q2 PAT of Rs98cr up by 32% yoy; Stock trades in green

JB Chem Q2 PAT up 32% YoY to Rs 98 crore

JB Chemicals & Pharmaceuticals Q2 results: Net profit up 32% to Rs 98 cr

JB Chemicals Consolidated September 2021 Net Sales at Rs 593.01 crore, up 33.69% Y-o-Y

India’s JB Chemicals and Pharmaceuticals Sept-Qtr Consol Net Profit Rises

Q1 FY22 Results Sheet

Disclosure of material event/information – Transcript of Earnings conference call – Q1 FY22

Q2 FY21 Results Sheet

Q1 FY21 Results Sheet

Q1 FY 22 Earnings Conference Call Transcript

Important communication with regard to TDS on dividend

Presentation made to Investors – 12.08.2021

Disclosure of material event/information – Newspaper Advertisement

Grant of Options under Employee Stock Option Scheme

Board to consider and declare interim dividend for FY 2020-21

Unaudited Financial Results 31.12.2020

Declaration of Interim Dividend

Press Release for Unaudited Financial Results – 31.12.2020

Presentation made to Investors – 10.02.2021

Schedule of meeting with institutional investors

Registration/ Log-in details for virtual call with management on 02.03.2021

Presentation made to Investors – 02.03.2021

Outcome of Board meeting

Institution of new Employee Stock Option Scheme

Launch of new dedicated division “RENOVA” to enter Nephrology segment in India

Disclosure of receipt of requests from the promoters/ promoter group members seeking re-classification of status as public

Notice of Board Meeting

Recommendation of final dividend

Schedule of Investors/ Analysts’ call with management on 15.06.2021 and Registration/Log-in details for the same

Audited Financial Results 31.03.2021

Recommendation of Final Dividend for FY 2020-21

Views of Board of Directors on the Reclassification Request

Press Release for Audited Financial Results – 31.03.2021

Newspaper cutting of extract of Consolidated Financial Results 31.03.2021

Instructions

Postal Ballot Form

Newspaper advertisement for Postal Ballot

Postal Ballot Notice – 25.06.2021

Results of Postal Ballot

Intimation of Record Date

Postal Ballot Form

Disclosure of material event/information – 02.07.2021

Notice of Annual general Meeting scheduled on September 9, 2021

Disclosure of material event/information – Change in Company Secretary & Compliance officer

Q4 FY20 Results Sheet

Q3 FY20 Results Sheet

Disclosure of material event/information –Institutional investors meet

Board to consider and declare interim dividend for F.Y. 2019-20

Declaration of Interim Dividend

Q1 FY20 Results Sheet

Annual Report of 2019-20

News about Ranitidine formulations in the US

Disclosure of material event/information – Supreme Court judgement on orders passed by National Green Tribunal

Notice of Board Meeting

Postal Ballot Notice

ANDA approval by US FDA

Press Release for Unaudited Financial Results – 30.06.2020

Recommendation of Final Dividend for FY 2019-20

Disclosure of material event/information – Public Announcement of open offer

Purchase of Pharmaceutical Business Undertaking of Lekar Pharma Limited

Disclosure of material event/information – Demise of Chairman & Managing Director Shri Jyotindra B. Mody

Notice of Annual General meeting published in news paper

Prior Public Notice with regard to convening of AGM through Video Conferencing (VC)/Other Audio Visual Means (OAVM)

Disclosure of material event/information Open Offer by Tau Investment Holdings Pte. Ltd.-Extension of time for dispatch of Letter of Offer granted by SEBI

Disclosure of material event/information – Purchase of Pharmaceutical Business Undertaking of Lekar Pharma Limited

Recommendation of Committee of Independent Directors (“IDC”) under Regulation 26(7) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, as amended

Change in Board of Directors

Resignation of Independent Directors

Notice of Board Meeting

Intimation of Record date

Advertisement for dispatch of Letter of offer

Notice of Annual General Meeting scheduled on September 24, 2020

Notice of Annual General meeting to be held on 30.09.2020 published in newspaper

Newspaper Cutting of extract of consolidated Unaudited Financial Results 30.09.2020

Result of voting on the business transacted at the Annual General Meeting held on 30-09-2020

Notice of Annual general Meeting scheduled on September 30, 2020

Announcement of Appointment of Mr. Nikhil Chopra as CEO

Disclosure of material event/ information – Resignation of a director 05.10.2020

Appointment of Chief Executive Officer & Whole-time Director

Letter of offer for Open Offer

Press Release for Unaudited Financial Results – 30.09.2020

Disclosure of material event/ information – Resignation of auditors 10.11.2020

Disclosure of material event/ information – Resignation of a director 10.11.2020

Disclosure of material event/ information – Appointment of auditors 10.11.2020

Result of Postal Ballot

Newspaper Advertisement for Postal Ballot

Schedule of meeting with institutional investors – 16.12.2020

Newspaper cutting of extract of Consolidated Unaudited Financial Results 31.12.2020

Intimation of Record Date

Disclosure of material event/ information – Appointment of Non-executive Director 10.02.2021

Disclosure of material event/ information – Resignation of a director 10.02.2021

Newspaper advertisement for Book Closure / Record Date

Recommendation of Final Dividend for FY 2020-21

Presentation made to Investors – 14.06.2021

Q4 FY21 Earnings Call Transcript

Newspaper cutting of extract of Consolidated Financial Results 31.03.2021

JB Chemicals Strong Run Of Growth Continues With International Rise

Earnings Conference Call on Q1 FY 21-22 – Audio recording

KKR-controlled drug maker JBCPL evaluating acquisition of select brands, mid-sized firm

KKR-backed JB Chemicals scouting for acquisitions

Q1 FY22 Earnings Call Audio

Postal Ballot Notice – 25.06.2021

Disclosure of material event/information – 02.07.2021

Press Release for Unaudited Financial Results – 30.06.2021

Newspaper advertisement for Postal Ballot

Intimation of Record Date

US FDA approval of New Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat

Successful US FDA inspection of Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat

Acquisition of Trademarks

Schedule of meeting with institutional investors 28.01.2020

Earnings Call

Earnings Call

Presentation made to Investors – 04.02.2020

J. B. Chemicals clears the confusion around Rantac® (Ranitidine)

Regulatory one-time increase in price of Metronidazole Formulations

Approval for re-classification of certain promoter group members to public

Draft Letter of Offer for Buy-back of Equity Shares

Public Announcement – Buy-back of shares

Outcome of Board Meeting – Buy-back of Equity shares by the Company

Intimation of Record Date for the proposed Buy-back of Equity shares by the Company

Letter of Offer for Buy-back of Equity Shares

Notice of Board Meeting – to consider & approve proposal for Buy-back

Notice of Board Meeting

News about presence of NDMA in Ranitidine

Press Release for Unaudited Financial Results – 30.09.2019

Disclosure of material event/information – Resignation of a director – 30.09.2019

FY20 Strategy Presentation

Disclosure of material event/information – September 12, 2019

Disclosure of material event/information – August 30, 2019

Disclosure of material event/information – August 28, 2019

Disclosure of material event/information – August 27, 2019

Result of voting on the business transacted at the Annual General Meeting held on 23-08-2019

Disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements), 2015 and Code for fair disclosure of UPSI

Recommendation of Dividend for FY 2018-19

Recommendation of Dividend

Notice of Board Meeting April/05/2019

Press Release for Audited Financial Results – 31.03.2019

Q4 FY19 Results Sheet

Notice of Board Meeting Jan/10/2019

Press Release for Unaudited Financial Results – 31.12.2017

Press Release for Unaudited Financial Results – 31.12.2018

Q3 FY19 Results Sheet

ANDA approval by US FDA

Update on disclosure of material event/information – November 5, 2018

Press Release for Unaudited Financial Results – 30.09.2018

Tender Form (demat shares)

Tender Form (physical shares)

Unaudited Financial Results 30.09.2018

Q2 FY19 Results Sheet

Post buyback Public Announcement

Notice of Annual General Meeting to be held on September 4, 2018

Result of voting on the business transacted at the Annual General Meeting held on 04-09-2018

Outcome of Board Meeting – Buy-back of Equity Shares by the Company

Intimation of Record Date for the proposed Buy-back of equity shares by the Company

Successful US FDA inspection of Solid Oral dosage forms formulations manufacturing facility at Panoli, Gujarat

Notice of Board Meeting – to consider & approve proposal for Buy-back

Public Announcement for Buy-back of Equity shares

Share transfer Form (physical shares)

Notice of Annual General Meeting published in Newspapers

Change in dividend payment date

Notice of Board Meeting

Press Release for Unaudited Financial Results – 30.06.2018

Q1 FY19 Results Sheet

Audited Financial Results 31.03.2018

Press Release for Audited Financial Results – 31.03.2018

Successful US FDA inspection of API Manufacturing facility at Panoli, Gujarat

Board Meeting Intimation

Disclosure of material event/information – April 24, 2018

Update on material event/ information – April 24, 2018

Disclosure of material event/ information – April 19,2018

Draft Letter of Offer for Buy-back of Equity Shares

Letter of Offer

Meeting with institutional investors

Schedule of meeting with institutional investors

Unadited Financial Results 31.12.2017

Notice of Board Meeting

Q2 FY18 Results Sheet

Press Release for Unaudited Financial Results – 30.09.2017

Notice of Annual General Meeting to be held on September 19, 2017

Result of voting on the business transacted at the Annual General Meeting held on 19-09-2017

Change in dividend payment date

Share transfer Form (physical shares)

Public Announcement for Buy-back of Equity shares

Notice of Board Meeting

Tender Form (demat shares)

Tender Form (physical shares)

Press Release for Unaudited Financial Results – 30.06.2017

Undited Financial Results 30.06.2017

Draft letter of offer for Buy-back of Equity shares

Post Buy-back Public Advertisement

Post Buy-back Public Advertisement

Recommendation of Dividend for the F.Y.2016-17

Intimation of Record Date for the proposed Buy-back of shares

Buy-back of Equity Shares

Board of Directors to consider the proposal for Buy-back of equity shares

Notice of Board Meeting

Recommendation of Dividend

Audited Financial Results 31.03.2017

Press Release for Audited Financial Results – 31.03.2017

Press Release for Audited Financial Results – 31.03.2017

Unaudited Financial Results 31.12.2016

Notice of Board Meeting

Resignation of a director – Dr. Niranjan Maniar

Notice of Board Meeting

Q2 FY17 Results Sheet

Press Release for Unaudited Financial Results – 30.09.2016

Resignation of a director – Mr. Jashvantrai Joshi

Notice of Annual General Meeting to be held on August 23, 2016

Result of voting on the business transacted at the Annual General Meeting held on 23-08-2016

Notice of Board Meeting

Update on material event/ information – 18 July 2016

Q1 FY17 Results Sheet

Press Release for Unaudited Financial Results – 30.06.2016

Recommendation of Final Dividend

Update on material event/ information – 19 May 2016

Notice of Board Meeting

Update on material event/ information – 31 March 2016

Press Release for Audited Financial Results – 31.03.2016

Resignation of a director – Mr. Mahesh K. Shroff

Update on material event/ information – 29 March 2016

Update on material event/ information – 11 March 2016

Declaration of Interim Dividend

Update on material event/ information – 4 March 2016

Update on material event/ information – 9 February 2016

Appointment of Independent director- Mr. Shaukat Merchant

Notice of Board Meeting

Disclosure of material event / information

Unaudited Financial Results 31.12.2015

Press Release for Unaudited Financial Results – 31.12.2015

Information under clause 36 of the Listing Agreement

Unaudited financial results 30.09.2015

Press Release for Unaudited Financial Results – 30.09.2015

Notice of Annual General Meeting to be held on August 19, 2015

Results of voting on the business transacted at the Annual General Meeting held on 19.08.2015

Recommendation of Special dividend and regular dividend

Intimation of change in dividend payment date

Intimation of Book Closure

Press Release for Unaudited Financial Results – 30.06.2015

Unaudited Financial Results 30.06.2015

Notice of Board Meeting

Audited Financial Results 2014 -15

Press Release for Audited Financial Results – 2014-15

Notice of Board Meeting

Q2 FY24 Press Release

Publication of 2nd Sustainability (ESG) Report

JB Pharma In News

Flu Season To Boost JB Pharma’s Volumes? | Nikhil Chopra Explains | Business News | ET Now

JB Pharma to go the Inorganic Way

JB Pharma bets big on chronic therapy for its growth aspirations

JB Pharma bets big on chronic therapy for its growth aspirations

JB Pharma places a large bet on chronic therapy in order to achieve its growth objectives

JB Pharma eyeing acquisitions to enter diabetes segment

Nikhil Chopra, CEO, JB Pharma at #ETREPharma Summit

Nikhil Chopra, CEO of JB Pharma, spoke to Moneycontrol about his company’s plans to enter the fast-growing probiotics and paediatric segments

More work needed to diagnose cardiovascular, hypertension problems: Nikhil Chopra, JB Pharma

KKR-led JB eyes acquisitions to grow faster

JB Chemicals closely watching for acquisition opportunities

KKR-owned JBCPL to aggressively scale up, acquire local drug brands

KKR-owned JBCPL to aggressively scale up, acquire local drug brands

Corporate Radar: Nikhil Chopra, CEO & Whole Time Director, J.B. Pharma In Exclusive Conversation With Zee Business

My role is to act like a catalyst

JB Chemicals new formulations for growth

We want to be known as good people for good health: Nikhil Chopra, CEO, JB

Top stocks in focus: Tata Steel, RailTel, Indiabulls Housing Finance, ZEEL, JB Chemicals & Pharma

Tata Steel, Sun Pharma, Zee, NMDC and more: Top stocks to watch out for on Nov 12

All you need to know going into trade on November 12

Buzzing stocks: Coal India, Zee Entertainment, Tata Steel and other stocks in news today

Business India Sept’21 Edition: JB Chemicals is all geared up to start its next growth phase!

Healthcare has started getting the type of attention it deserves

My role is to act like a catalyst

How will Pharma 2021 unfold?